Evidence map›Paper›PMID 41443752›Full record

ArticleJournal of proteome research2026

Penicillin-Streptomycin Treatment Rewires Core Metabolic and Ribosomal Programs in HepG2 Cells.

Cameron S Movassaghi, Jesse G Meyer

Abstract read
In one paragraph

Article in Journal of proteome research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Cameron S MovassaghiDepartment of Computational Biomedicine, Cedars Sinai Medical Center, Los Angeles California 90048, United States.
Jesse G MeyerDepartment of Computational Biomedicine, Cedars Sinai Medical Center, Los Angeles California 90048, United States.ORCID 0000-0003-2753-3926

Funding

Democratizing Multi-Omics to Expedite Discovery of Hidden Metabolic PathwaysR35GM142502 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI MEYER, JESSE · 2021 to 2025
$2.2M
NIGMS NIH HHS R35 GM142502
6 · The paper itself

Abstract

Antibiotics are routinely added to mammalian cell culture media to prevent bacterial growth. However, the use of antibiotics in a cell culture can confound downstream experimental results. While genomic and transcriptomic differences between cell cultures treated with and without antibiotics are well-documented, far fewer, if any, comprehensive proteomic comparisons on the use of antibiotics in cell culture have been performed. Here, we present a study on the proteome-wide differences of culturing HepG2 cells in antibiotic (i.e., penicillin/streptomycin) and nonantibiotic-containing media. Using a longitudinal and crossover treatment study design, we analyzed 119 samples across nine passages and four conditions. On average, 9,374 proteins were detected per sample, and we identified 383 proteins that were differentially abundant between conditions. These changes included ribosomal and mitochondrial proteins, demonstrating that off-target effects of antibiotics on mammalian cells occur at the protein level. Linear mixed-effect modeling suggested that the proteomic impact of antibiotic treatment is strongest in the first passage after treatment and stabilizes after approximately three passages. Furthermore, initiating antibiotic treatment induced a greater number of differentially abundant proteins than discontinuing treatment. Lastly, we compared our results to existing literature on the use of common antibiotics in mammalian cell culture. We identified proteins and pathways conserved across studies, omics layers, and cell types. We hope that this detailed proteomic survey of the ubiquitous pencillin-streptyomcin-treated HepG2

Indexed as

Anti-Bacterial AgentsPenicillinsProteomeRibosomesStreptomycinHep G2 CellsHumansProteomicsRibosomal ProteinsAnti-Bacterial AgentsPenicillinsProteomeRibosomal ProteinsStreptomycinantibioticsHepG2lipid metabolismmetabolismmitochondriaproteomicsribosome

Identifiers

PMID41443752
PMCPMC12888007

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.